TWST: Record FY26 revenue and positive Q4 adjusted EBITDA set up another growth year

What happened

Twist Bioscience reported FY26 revenue of $459.4 million, up 22%, and gross margin of 52.4%. Adjusted EBITDA, a measure of operating performance before certain costs, turned positive in the fourth quarter. For FY27, the company targets $550 million to $560 million in revenue and positive adjusted EBITDA, with $75 million in planned capital spending.

Confirmed

Global impact / market context

The revenue target implies further growth, while positive adjusted EBITDA suggests the company expects operating performance to remain above zero on that measure. Planned $75 million in capital spending could support expansion but also uses cash, so delivery on sales and spending plans matters to future finances.

Analyst inference

The supplied information points to a company balancing growth with operating improvement: FY26 sales rose and fourth-quarter adjusted EBITDA became positive, while FY27 guidance pairs higher targeted revenue with continued investment. Investors may weigh the growth outlook against the cash required for planned capital spending.

Analyst inference

What to watch

1. Whether FY27 revenue reaches the $550 million to $560 million target; results below that range could weaken the growth case, while meeting it would support guidance. Analyst inference
2. Whether adjusted EBITDA remains positive through FY27, since this would indicate the company is sustaining operating improvement as revenue grows. Analyst inference
3. Whether the company carries out its planned $75 million in capital spending and how that investment relates to revenue growth and cash available. Analyst inference

Evidence

• Original source link unavailable